圖／翻攝自臉書陳念琴﹣I’m Nien-Chin,CHEN https://www.vogue.com.tw/article/boxer-nien-chin-chen

Chen Nien-chin is known as the cancer-beating boxing queen (抗癌拳后) in #Taiwan.

Chen was diagnosed with stage II Hodgkin #lymphoma in 2019 and underwent 8 rounds of chemotherapy before returning to the ring for the Tokyo Olympics.

She only made her win over #cancer public in 2021.

What a fighter! 🫶

Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma | CancerNetwork The next frontier is not only building constructs that reduce one mechanism of relapse, but understanding why antigen-positive failures still occur.

Worth the read if you care about where lymphoma therapy is heading.

www.cancernetwork.com/view/rethink...

#OncTwitter #CAR-T #Lymphoma #Immunotherapy

💡Missed a HemeHub webinar?

All past sessions are available to watch anytime on YouTube!

Sessions organized by topic can also be viewed directly on our website.

🌐Explore more: hemehub.org

#HemeHub #Hematology #MedicalEducation #HemeOnc #BMF #Lymphoma #BleedingDisorders #ThromboticDisorders

Close up of five petaled pink flowers of the Common Periwinkle against green foliage.

A large bed five petaled pink flowers of the Common Periwinkle against green foliage.

I'm reminded when I see the Common Periwinkle - Vinca Major of a related plant, the Madagascar Periwinkle - Vinca Rosea. It's the source of Vincristine, a #chemotherapy drug that those of us who have #Lymphoma behind us are grateful for.

Lonza to manufacture ImmuneOncia’s antibody for lymphoma Lonza partners with ImmuneOncia to manufacture Danburstotug, a promising mAb therapy for rare NK/T-cell lymphoma, advancing to Phase III trials.

Lonza announced it has inked a deal with ImmuneOncia to produce a monoclonal antibody (mAb) therapy. The treatment will target refractory NK/T-cell lymphoma, a rare form of blood cancer.

Read my full article below:
#lymphoma #blood #antibody

www.bioprocessintl.com/deal-making/...

🌐Enhance your hematology knowledge with HemeHub webinars, available anytime.

All past sessions are organized by topic directly on our website and are also available on YouTube.

🔗 Learn more at hemehub.org

#HemeHub #Hematology #HemeEd #HemeOnc #BMF #Lymphoma #BleedingDisorders #ThromboticDisorders

Donate to Support Danny Reyes's Cancer Journey, organized by John Benavides Uncle Danny has always been the kind of person who shows up, no matter what. Growi… John Benavides needs your support for Support Danny Reyes's Cancer Journey

My family would really appreciate any donations towards my Tio's journey with his recent lymphoma diagnosis. He's a wonderful person and is ALWAYS helping others out 💜 #cancer #lymphoma #donations #donate #gofundme

Is CAR T-cell therapy right for you?

Learn about candidates, risks, outcomes, and quality of life after treatment.

🗓 May 5
🕞 3:45 p.m. ET | 2:45 p.m. CT | 1:45 p.m. MT | 12:45 p.m. PT

Register: bmtinfonet.org/registration...

#CARTCellTherapy #Lymphoma #BMTInfoNet #CancerSurvivorship

In patients with R/R follicular #lymphoma, treatment with the triplet combo of #tafasitamab, #lenalidomide, and #rituximab led to significantly improved PFS compared with the SOC combo of lenalidomide plus rituximab, at a median 22.4 months vs. 13.9: https://ow.ly/PSaT50YBgcw
#HemeSky

Sickle Cell Disease: From Diagnosis to Cure by #MelissaFreiJones: ASPHO is proud to partner with Mediaplanet in the Blood Health supplement in USA TODAY 3/25-27. #BloodDisorder—including #blood #cancers #leukemia #lymphoma #multiplemyeloma #research uthealthsa.bsky.social

Targeting UHRF1 induces regression of aggressive mantle cell lymphoma - PubMed Although targeting the ubiquitin-like PHD and RING finger domain-containing protein 1 (UHRF1) has shown promise in treating a number of diseases, its function in mantle cell lymphoma (MCL) and its regulatory connection to SOX11 are yet unknown. Our study showed that UHRF1 is markedly upregulated in …

A new target identified - something to watch for the treatment of Mantle Cell #lymphoma Targeting UHRF1 induces regression of aggressive mantle cell lymphoma Preclinical. No trials yet.
share.google/aimode/GHnPt...

pubmed.ncbi.nlm.nih.gov/41876725/

🩸 #sfh2026 #Hematology #OncoHematology #Waldenström #IWMF #Immunology #Lymphoma #WomenInSTEM #GustaveRoussy #WeillCornell #StemCells #ApostolouLab #MelnickLab

Single-cell and #SpatialTranscriptomics of primary testicular #DLBCL reveal an exhausted CD8⁺ T cell–dominated microenvironment and spatial immune architecture, with E2F and CREB inhibition suppressing #lymphoma proliferation and #tumor growth.

#OpenAccess: doi.org/10.1016/j.ge...

Looking into lymphoma treatment abroad?

Mexico offers advanced immunotherapy like checkpoint inhibitors and CAR T-cell therapy. 
www.placidway.com/answer-detail/571379/Wha...

#Lymphoma #Immunotherapy  #MedicalTourism

Sage Journals: Discover world-class research Subscription and open access journals from Sage, the world's leading independent academic publisher.

This study aims to unravel relationship b/w apolipoprotein C1 levels, prognostic nutritional index, and clinicopathological characteristics in patients with diffuse large B-cell #lymphoma and their prognostic predictive value.

journals.sagepub.com/share/4YV5WF...

@womeninlymphoma.bsky.social

Influencer Dies at 29 After Mistaking Initial Cancer Symptoms as Strain from Work Wang Weiqian revealed her lymphoma diagnosis in 2021, and she continued to document her health journey for over 18,000 social media followers

#Discover #Cancer #WangWeiqian #Lymphoma 💔🌹

www.yahoo.com/entertainmen...

Your story matters. By sharing your experience in the Global Patient Survey on Lymphomas & CLL, you help drive better care, smarter research and real change worldwide.

Take part today: bit.ly/LCSurveyInfo

#GlobalPatientSurvey #PatientExperience #Lymphoma #CLL #PatientVoice

FDA approves nivolumab with chemotherapy for Hodgkin lymphoma FDA approved approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for cHL.

The FDA has approved nivolumab (Opdivo) with AVD chemotherapy as first‑line treatment for stage III–IV classical Hodgkin lymphoma in patients 12 and older, officially bringing immunotherapy into frontline care. #Lymphoma #Immunotherapy #TCSC
www.fda.gov/drugs/resour...

As the Global Burden of Hodgkin Lymphoma Decreases, Disparities Persist Incidence of Hodgkin lymphoma has decreased globally and is projected to continue to decrease through 2035, but lower SDI regions demonstrated more modest decreases in HL incidence and mortality.

Analysis of #HodgkinLymphoma burden from 1990–2019 reveals a 31.2% increase in global cases. Significant disparities persist in mortality rates and access to care across varying sociodemographic regions.

Read the review: ➡️ https://bit.ly/4uMFfui

#lymsm #globalhealth #lymphoma

EPA moves to weaken pollution limits on chemical used to sterilize medical equipment The Environmental Protection Agency has proposed weakening air pollution limits for a chemical used to sterilize medical equipment.

#MAHA needs to stop the #EPA proposal to weaken pollution limits on ethylene oxide (#EtO), a cancer-causing chemical.

Breathing it long-term significantly increases the risk of developing #leukemia, #lymphoma, and #breastcancer for facility workers and the people living nearby.

High-Dose Cytarabine Maximizes CD34 Cell Yield Without Improving Survival in PCNSL High-dose cytarabine achieved 100% stem cell mobilization success in PCNSL patients undergoing autologous transplantation.

High-dose cytarabine (HD-Ara-C)-based mobilization achieved universal stem cell collection and the highest CD34⁺ yields in primary central nervous system lymphoma (#PCNSL), yet did not confer a progression-free survival advantage.

Read more: https://bit.ly/4rGQcuL

#RareDisease #Lymphoma

Among patients with follicular #lymphoma, adding #epcoritamab to the SOC combo of #lenalidomide plus #rituximab outperformed lenalidomide plus rituximab alone, resulting in ORRs of 95% vs. 79%, as well as a lower risk of disease progression or death: https://ow.ly/652R50YrQeT
#HemeSky #MedSky

A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies - PubMed CD19 chimeric antigen receptor (CAR) T-cell therapy has become the standard of care in relapse and/or refractory B-cell malignancies. Up to 30% to 60% of patients experience relapsed disease because of the emergence of CD19low or CD19- tumor cell clones. Although bispecific CD19/CD22 CAR T cells hav …

B-cell #Lymphoma treatments continue to advance: you can target and kill the mature forms of b-cells and more will regenerate from stem cells. The immature cells don't yet have the cd20, or cd19, or cd22 molecule on the cell surface.

pubmed.ncbi.nlm.nih.gov/41100732/

The Targeted Pulse: Updates in Breast, Lung, and Lymphoma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Oncology shifts fast: tazemetostat pulled, giredestrant PFS miss, and new ADC and NSCLC guideline strategies refine metastatic care.

Cancer treatment never stands still. New updates across #breastcancer, #lungcancer and #lymphoma show how rapidly #oncology is evolving, with new ADC strategies, trial results and guideline shifts shaping metastatic care.
#OncologyNews #CancerResearch #TCSC
www.targetedonc.com/view/the-tar...

Original post on masto.ai

…inhaling the gas can cause coughing, dizziness, fatigue & nausea. Long-term exposure can damage the #brain & central nervous system & can increase the risk of breast #cancer, #leukemia, #lymphoma & other #cancers of the white blood cells.

The #EPA first classified #EthyleneOxide as a human […]

Researchers identified proteomic markers for #LymphoidCancer risk up to 10yrs before diagnosis. This large-scale discovery reveals how early molecular signatures like sCD23 can drive risk stratification & #EarlyDetection

rdcu.be/e6GBZ%E2%80%8B

#Proteomics #PrecisionMedicine #Biomarkers #Lymphoma

Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma - PubMed This study assessed real-world effectiveness and safety of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), including those with high-risk disease, secondary central nervous system (sCNS) involvement, comorbidities, and poor fitness, using …

New study led by Dr. Iris Isufi shows liso-cel has strong real-world effectiveness in R/R large B-cell #lymphoma (ORR 81%, CR 71%) with consistent outcomes even in high-risk patients—supporting use across a broad patient population.
pubmed.ncbi.nlm.nih.gov/41774517/
@oncoalert.bsky.social

Early View | Haematologica

Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell #lymphoma: results from EPCORE NHL-2 haematologica.org/article/view... #hvhebron #hemat [Text complet]

NEWS
You Might Have Missed

@lymphomacancerawareness
@rhhs_lls
@non_hodgkins_lymphoma
@lymphomacommunity

#lymphoma #health #wellness #mmj #mmjpatient #mmjcommunity #selfcare #healthcare #patientcare #eduction #care

🎯#CaseReport A 69-year-old male patient with mantle cell #lymphoma accompanied by eosinophilia➡️Following immunochemotherapy, the Pt achieved lymphoma remission, and eosinophil levels returned to normal

journals.sagepub.com/share/UDQ44M...

#CanSky #OncoSky